| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 89 | 102 | 43 | 65 |
| Depreciation and amortization | 2 | 2 | 3 | 5 |
| Amortization of right-of-use assets | 2 | 3 | 2 | 5 |
| Stock-based compensation expense | 9 | 5 | 7 | 14 |
| Unrealized loss on equity investments | NaN | 1 | 0 | -1 |
| Loss on debt extinguishment | -18 | NaN | NaN | NaN |
| Deferred income taxes | 27 | -38 | -15 | 7 |
| Acquired in-process research and development | NaN | 0 | 0 | NaN |
| Impact from foreign exchange movements | 0 | -3 | -3 | 5 |
| Other adjustments, net | 2 | NaN | -1 | -1 |
| Accounts receivable | 20 | -6 | 18 | -15 |
| Current inventories | 1 | -2 | 6 | -22 |
| Other current and noncurrent assets | 18 | -11 | -7 | -31 |
| Impairment of tangible and intangible assets | 6 | 3 | 16 | 0 |
| Accrued legal and settlement expenses | -38 | -310 | 2 | -60 |
| Other current and noncurrent liabilities | -86 | -8 | -82 | 131 |
| Net cash (used in) provided by operating activities | -9 | -221 | -39 | 158 |
| Purchases of property and equipment | 20 | 24 | 20 | 17 |
| Purchases of in-process research and development and intangible assets | NaN | 0 | 0 | 1 |
| Acquisitions, net of cash acquired | NaN | 0 | NaN | NaN |
| Purchases of investments in debt securities | 5 | 6 | 3 | 6 |
| Sales of equity securities | NaN | 1 | NaN | NaN |
| Sales and maturities of debt securities | 6 | 5 | 3 | 11 |
| Other proceeds from investing activities | NaN | 0 | NaN | NaN |
| Net cash used in investing activities | -19 | -24 | -20 | -17 |
| Proceeds from the issuance of common stock | 0 | 0 | 1 | 0 |
| Cash paid for repurchases of common stock | 126 | 0 | 0 | 0 |
| Proceeds from debt, net | 489 | 0 | NaN | NaN |
| Repayments of debt | 333 | 5 | 4 | 4 |
| Transaction costs related to debt refinancing | 5 | 0 | NaN | NaN |
| Settlement of equity awards | 21 | 2 | 0 | 0 |
| Other | 3 | NaN | NaN | 0 |
| Net cash provided by (used in) financing activities | 7 | -5 | -3 | -5 |
| Net (decrease) increase in cash and cash equivalents | -20 | -252 | -61 | 189 |
| Exchange differences | 0 | 0 | -2 | 1 |
| Cash and cash equivalents at beginning of period | 195 | 445 | 510 | 372 |
| Cash and cash equivalents at end of period | 175 | 195 | 445 | 510 |
Indivior Pharmaceuticals, Inc. (INDV)
Indivior Pharmaceuticals, Inc. (INDV)